Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison

Objective To compare improvement in pain and physical function for patients treated with baricitinib, adalimumab, tocilizumab and tofacitinib monotherapy from randomised, methotrexate (MTX)-controlled trials in conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)/biologic (bDMARD)...

Full description

Bibliographic Details
Main Authors: P Emery, M Van de Laar, R Fleischmann, B Fautrel, P C Taylor, I De La Torre, B Zhu, F De Leonardis, C L Kannowski, C Nicolay, Z Kadziola
Format: Article
Language:English
Published: BMJ Publishing Group 2020-02-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/6/1/e001131.full

Internet

https://rmdopen.bmj.com/content/6/1/e001131.full

Similar Items